VCA Stocks

aTyr Pharma, a privately held biopharmaceutical company focused on identifying and developing a novel class of naturally occurring protein biologics for human therapeutics, today announced the closing of its $10.5 million Series B financing aTyr’s biologics have therapeutic potential across a wide range of disease areas including vascular, inflammation, oncology, metabolic, neurologic and dermatologic disorders. Regenerative Medicine